Literature DB >> 26746433

Multiple sclerosis-like diagnosis as a complication of previously treated malaria in an iron and vitamin D deficient Nigerian patient.

Susan J van Rensburg1, Ronald van Toorn2, Kelebogile E Moremi3, Armand V Peeters4, Adesola Oguniyi5, Maritha J Kotze4.   

Abstract

In contrast to malaria, multiple sclerosis (MS) is infrequently found in Black Africans. We describe a 29 year old Nigerian female who developed an MS-like condition with symptoms similar to relapsing-remitting MS following malaria infection, leading to a diagnosis of MS. However, absence of hyperintense lesions in the brain and spinal cord presented a conundrum since not all the diagnostic criteria for MS were met. Pathology supported genetic testing (PSGT) was applied to combine family and personal medical history, lifestyle factors, and biochemical test results for interpretation of genetic findings. This approach provides a means of identifying risk factors for different subtypes of demyelinating disease. The patient was subsequently treated according to an individualised intervention program including nutritional supplementation as well as a change in diet and lifestyle. Deficiencies of vitamin B12, iron and vitamin D were addressed. Genetic analysis revealed absence of the HLA DRB1*1501 allele, considered to be the most prominent genetic risk factor for MS. Extended mutation analysis identified variations in three genes in the folate-vitamin B12 metabolic pathway, which could have increased the patient's sensitivity to the antifolate drugs used to treat the malaria. A glutathione-S-transferase GSTM1 null allele, previously associated with neurological complications of malaria, was also detected. Furthermore, a heterozygous variation in the iron-related transmembrane protease serine 6 (TMPRSS6) gene, rs855791 was found, which could have impacted the patient's iron status following two successive blood donations and exposure to malaria preceding the MS diagnosis. PSGT identifies relevant risk factors for demyelinating disorders resembling MS and uses the data for individualised treatment programs, and to systematically build a database that can provide evidence in large patient cohorts. Follow-up investigations may be suggested, such as whole exome sequencing in selected cases, to ensure that remyelination and restoration of function are achieved.

Entities:  

Keywords:  Diet; Genetics; Iron; Malaria; Multiple sclerosis; Vitamin B12; Vitamin D

Mesh:

Substances:

Year:  2016        PMID: 26746433     DOI: 10.1007/s11011-015-9788-4

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  60 in total

1.  Postmalaria neurological syndrome: a case of acute disseminated encephalomyelitis?

Authors:  A H Mohsen; M W McKendrick; M L Schmid; S T Green; M Hadjivassiliou; C Romanowski
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-03       Impact factor: 10.154

Review 2.  Non-MS recurrent demyelinating diseases.

Authors:  Vesna V Brinar
Journal:  Clin Neurol Neurosurg       Date:  2004-06       Impact factor: 1.876

Review 3.  Cellular iron uptake, trafficking and metabolism: Key molecules and mechanisms and their roles in disease.

Authors:  D J R Lane; A M Merlot; M L-H Huang; D-H Bae; P J Jansson; S Sahni; D S Kalinowski; D R Richardson
Journal:  Biochim Biophys Acta       Date:  2015-02-04

Review 4.  Environmental factors in multiple sclerosis.

Authors:  Alberto Ascherio
Journal:  Expert Rev Neurother       Date:  2013-12       Impact factor: 4.618

5.  Can we predict multiple sclerosis?

Authors:  Sreeram V Ramagopalan; Gavin Giovannoni
Journal:  Lancet Neurol       Date:  2009-10-29       Impact factor: 44.182

6.  Iron status in children with recurrent episodes of tumefactive cerebral demyelination.

Authors:  Ronald van Toorn; Johan F Schoeman; Regan Solomons; Megan A Rensburg; Susan J van Rensburg
Journal:  J Child Neurol       Date:  2010-04-15       Impact factor: 1.987

7.  Is the acronym IRIDA acceptable for slow responders to iron in the presence of TMPRSS6 mutations?

Authors:  Ebru Yilmaz-Keskin; Ertan Sal; Luigia de Falco; Mariasole Bruno; Achille Iolascon; Ulker Koçak; Idil Yenicesu
Journal:  Turk J Pediatr       Date:  2013 Sep-Oct       Impact factor: 0.552

8.  A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?

Authors:  N M van der Put; F Gabreëls; E M Stevens; J A Smeitink; F J Trijbels; T K Eskes; L P van den Heuvel; H J Blom
Journal:  Am J Hum Genet       Date:  1998-05       Impact factor: 11.025

Review 9.  Biochemical pathogenesis of subacute combined degeneration of the spinal cord and brain.

Authors:  R Surtees
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

10.  Common variants in TMPRSS6 are associated with iron status and erythrocyte volume.

Authors:  Beben Benyamin; Manuel A R Ferreira; Gonneke Willemsen; Scott Gordon; Rita P S Middelberg; Brian P McEvoy; Jouke-Jan Hottenga; Anjali K Henders; Megan J Campbell; Leanne Wallace; Ian H Frazer; Andrew C Heath; Eco J C de Geus; Dale R Nyholt; Peter M Visscher; Brenda W Penninx; Dorret I Boomsma; Nicholas G Martin; Grant W Montgomery; John B Whitfield
Journal:  Nat Genet       Date:  2009-10-11       Impact factor: 38.330

View more
  4 in total

1.  Fractional anisotropy of white matter, disability and blood iron parameters in multiple sclerosis.

Authors:  Estelle Herbert; Penelope Engel-Hills; Coenraad Hattingh; Jean-Paul Fouche; Martin Kidd; Christine Lochner; Maritha J Kotze; Susan J van Rensburg
Journal:  Metab Brain Dis       Date:  2018-02-02       Impact factor: 3.584

Review 2.  Pathology-supported genetic testing as a method for disability prevention in multiple sclerosis (MS). Part II. Insights from two MS cases.

Authors:  Susan J van Rensburg; Coenraad Hattingh; Clint Johannes; Kelebogile E Moremi; Armand V Peeters; Carel J van Heerden; Rajiv T Erasmus; Annalise E Zemlin; Merlisa C Kemp; Mariaan Jaftha; Aye Aye Khine; Felix C V Potocnik; Lindiwe Whati; Penelope Engel-Hills; Ronald van Toorn; Maritha J Kotze
Journal:  Metab Brain Dis       Date:  2021-03-12       Impact factor: 3.584

Review 3.  Pathology-supported genetic testing as a method for disability prevention in multiple sclerosis (MS). Part I. Targeting a metabolic model rather than autoimmunity.

Authors:  Susan J van Rensburg; Ronald van Toorn; Rajiv T Erasmus; Coenraad Hattingh; Clint Johannes; Kelebogile E Moremi; Merlisa C Kemp; Penelope Engel-Hills; Maritha J Kotze
Journal:  Metab Brain Dis       Date:  2021-04-28       Impact factor: 3.584

4.  Identification of an iron-responsive subtype in two children diagnosed with relapsing-remitting multiple sclerosis using whole exome sequencing.

Authors:  Susan J van Rensburg; Armand V Peeters; Ronald van Toorn; Johan Schoeman; Kelebogile E Moremi; Carel J van Heerden; Maritha J Kotze
Journal:  Mol Genet Metab Rep       Date:  2019-03-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.